Steroid hormone modulation of 3H-prostaglanding E1 binding to bovine corpus leteum cell membranes.
The specific binding of 3H-prostaglandin E1 (3H-PGE1) to bovine corpus luteum cell membranes was not affected by cholesterol or various progestins at concentrations of up to 9.0x10-minus-6M. At concentrations  above 2.5 x 10-minus-6M; estrone, 17beta-estradiol (but not 17alpha-estradiol or 17beta-estradiol glucuronide), estroil, equilin, D-equilenin, 17-ethynyl estradiol, diethylstilbestrol, cortisol, corticosterone, deoxycorticosterone and aldosterone inhibited specific binding of 3H-PGE1. On the other hand, testosterone and dihydrotestosterone (DHT) (but not androstenedione) significantly enhanced 3H-PGE1 binding. These findings permitted the following correlations between steroid structure and modulation of 3H-PGE1 binding: steroids with a free phenolic ring and a 17beta-hydroxyl or 17-keto group or C-21 steroids with a C-20 ketone and a C-21 hydroxy group decrease, whereas C-19 steroids with a C-17 hydroxy group enhance specific binding of 3H-PGE1. PGE receptors are heterogeneous with respect to affinity for 3H-PGE1. The steroids that decreased 3H-PGE1 binding caused a lowering to a complete loss of low affinity PGE receptors. Steroids that increased 3H-PGE1 binding caused appearance of new low affinity PGE receptors. Association rate constants for 3H-PGE1 binding were decreased by 17beta-estradiol (61%) and increased by DHT (59%).
D000450:Aldosterone / Q000494:pharmacology; D000818:Animals; D002417:Cattle; D002462:Cell Membrane / Q000378:metabolism; D002784:Cholesterol / Q000494:pharmacology; D003338:Corpus Luteum / Q000378:metabolism*; D003345:Corticosterone / Q000494:pharmacology; D003348:Cortisone / Q000494:pharmacology; D003864:Depression, Chemical; D003900:Desoxycorticosterone / Q000494:pharmacology; D004054:Diethylstilbestrol / Q000494:pharmacology; D013196:Dihydrotestosterone / Q000494:pharmacology; D004855:Equilenin / Q000494:pharmacology; D004857:Equilin / Q000494:pharmacology; D004958:Estradiol / Q000494:pharmacology; D004964:Estriol / Q000494:pharmacology; D004970:Estrone / Q000494:pharmacology; D004997:Ethinyl Estradiol / Q000494:pharmacology; D005260:Female; D011372:Progestins / Q000494:pharmacology*; D011458:Prostaglandins E / Q000378:metabolism*; D011956:Receptors, Cell Surface; D013268:Stimulation, Chemical; D013329:Structure-Activity Relationship; D013739:Testosterone / Q000494:pharmacology
D011372:Progestins; D011458:Prostaglandins E; D011956:Receptors, Cell Surface; D013196:Dihydrotestosterone; D004857:Equilin; D004970:Estrone; D013739:Testosterone; D003900:Desoxycorticosterone; D004997:Ethinyl Estradiol; D000450:Aldosterone; D004958:Estradiol; D004054:Diethylstilbestrol; D002784:Cholesterol; D004964:Estriol; D003348:Cortisone; D004855:Equilenin; D003345:Corticosterone